Results from the late-breaking TWILIGHT trial suggest that, among high-risk patients who have undergone PCI and completed three months of dual antiplatelet therapy, it’s safer to continue treatment with ticagrelor alone rather than add aspirin to that cocktail.

A shortened, three-month course of dual antiplatelet therapy might be a safer bet than 12-month treatment for patients at a high risk of bleeding after PCI and implantation of a drug-eluting stent.

The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

NEW ORLEANS — An antithrombotic regimen of apixaban plus a P2Y12 inhibitor such as clopidogrel lowered bleeding events and hospitalizations compared to warfarin plus clopidogrel in a cohort of patients with atrial fibrillation (AFib) and a recent acute coronary syndrome (ACS), according to results of the AUGUSTUS trial.

P2Y12 inhibitor initiation with clopidogrel using a loading dose (LD) is no more effective in reducing ischemic events or adverse outcomes in transcatheter aortic valve implantation (TAVI) patients than initiating the therapy without a loading dose, according to research published in the American Journal of Cardiology Feb. 10.

Tafamidis, Pfizer’s treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), has been granted a priority review designation from the FDA, potentially speeding its path to approval.

Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.

Cleveland Clinic researchers identified amyloid deposits in 10.2 percent of patients undergoing carpal tunnel release surgery, suggesting biopsies of hand tissue could be an early signal of life-threatening cardiac amyloidosis.